Europe’s biotechnology firms have historically struggled to raise funds on a par with US counterparts when going public, often not having the familiarity with US investors necessary to achieve a successful flotation.
European Biotechs Enter the IPO Big League
Genmab's NASDAQ Debut Biggest of 2019
2019 has seen European biotech companies making waves in the US IPO space. Genmab’s listing was a blockbuster, but many more companies have proven their ability to go public on the NASDAQ.
More from Business
More from Scrip
• By
The San Diego biotech’s lead product candidate is an antisense oligonucleotide-based therapy slated to enter Phase III development in the third quarter.
• By
The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.
• By
Merck is investing $ 1bn in a Delaware facility to produce Keytruda and expand biologics manufacturing amid US tariff concerns.